Isoxazole-type derivatives related to combretastatin A-4, synthesis and biological evaluation

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 12, 2006, Pages 4067-4077

  Kaffy, Julia ^a   Pontikis, Renée ^a   Carrez, Danièle ^b   Croisy, Alain ^b   Monneret, Claude ^a   Florent, Jean Claude ^a  

^a INSTITUT CURIE   (France)

^b Centre Universitaire   (France)

Author keywords

1,3 Dipolar cycloaddition tubulin; Combretastatin; Cytotoxicity; Isoxazole

Indexed keywords

3 (3 HYDROXY 4 METHOXYPHENYL) 5 (3,4,5 TRIMETHOXYPHENYL) 1,2,4 DIOXAZOLE; 3 (3 HYDROXY 4 METHOXYPHENYL) 5 (3,4,5 TRIMETHOXYPHENYL) 1,2,4 OXADIAZOLE; 3 (3 HYDROXY 4 METHOXYPHENYL) 5 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDROISOXAZOLE; 3 (3 HYDROXY 4 METHOXYPHENYL) 5 (3,4,5 TRIMETHOXYPHENYL)ISOXAZOLE; 3 [3 (TERT BUTYLDIMETHYLSILANYLOXY) 4 METHOXYPHENYL] 5 (3,4,5 TRIMETHOXYPHENYL) 1,2,4 DIOXAZOLE; 3 [3 (TERT BUTYLDIMETHYLSILANYLOXY) 4 METHOXYPHENYL] 5 (3,4,5 TRIMETHOXYPHENYL) 1,2,4 OXADIAZOLE; 3 [3 (TERT BUTYLDIMETHYLSILANYLOXY) 4 METHOXYPHENYL] 5 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDROISOXAZOLE; 3 [3 (TERT BUTYLDIMETHYLSILANYLOXY) 4 METHOXYPHENYL] 5 (3,4,5 TRIMETHOXYPHENYL)ISOXAZOLE; 4 (3 HYDROXY 4 METHOXYPHENYL) 5 (3,4,5 TRIMETHOXYPHENYL)ISOXAZOLE; 5 (3 HYDROXY 4 METHOXYPHENYL) 3 (3,4,5 TRIMETHOXYPHENYL) 1,2,4 DIOXAZOLE; 5 [3 (TERT BUTYLDIMETHYLSILANYLOXY) 4 METHOXYPHENYL] 3 (3,4,5 TRIMETHOXYPHENYL) 1,2,4 DIOXAZOLE; 5 [3 (TERT BUTYLDIMETHYLSILANYLOXY) 4 METHOXYPHENYL] 3 (3,4,5 TRIMETHOXYPHENYL)ISOXAZOLE; A 105972; A 289099; ANTINEOPLASTIC AGENT; C (3 HYDROXY 4 METHOXYPHENYL) N (3,4,5 TRIMETHOXYPHENYL)NITRONE; COMBRETASTATIN A4; ETHYL 3 (3 HYDROXY 4 METHOXYPHENYL) 4 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDROISOXAZOLE 5 CARBOXYLATE; ETHYL 3 (3 HYDROXY 4 METHOXYPHENYL) 5 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDROISOXAZOLE 4 CARBOXYLATE; ETHYL 3 [3 (TERT BUTYLDIMETHYLSILANYLOXY) 4 METHOXYPHENYL] 5 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDROISOXAZOLE 4 CARBOXYLATE; ETHYL 3 [3 (TERT BUTYLDIMETHYLSILANYLOXY) 4 METHOXYPHENYL] 5 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDROISOXAZOLE 5 CARBOXYLATE; ISOXAZOLE DERIVATIVE; ISOXAZOLINE DERIVATIVE; METHYL 3 (3 HYDROXY 4 METHOXYPHENYL) 2 (3,4,5 TRIMETHOXYPHENYL) ISOXAZOLIDINE 4 CARBOXYLATE; N,N DIETHYL 3 (3 HYDROXY 4 METHOXYPHENYL) 4 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDROISOXAZOLE 5 CARBOXAMIDE; N,N DIETHYL 3 (3 HYDROXY 4 METHOXYPHENYL) 5 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDROISOXAZOLE 4 CARBOXAMIDE; N,N DIETHYL 3 [3 (TERT BUTYLDIMETHYLSILANYLOXY) 4 METHOXYPHENYL] 5 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDROISOXAZOLE 4 CARBOXAMIDE; N,N DIETHYL 3 [3 (TERT BUTYLDIMETHYLSILANYLOXY) 4 METHOXYPHENYL] 5 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDROISOXAZOLE 5 CARBOXAMIDE; N,N DIETHYL 4 (3 HYDROXY 4 METHOXYPHENYL) 3 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDROISOXAZOLE 5 CARBOXAMIDE; N,N DIETHYL 4 [3 (TERT BUTYLDIMETHYLSILANYLOXY) 4 METHOXYPHENYL] 3 (3,4,5 TRIMETHOXYPHENYL) 4,5 DIHYDROISOXAZOLE 5 CARBOXAMIDE; OXADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PROTEIN BINDING;

BRAIN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; HUMANS; ISOXAZOLES; MOLECULAR STRUCTURE; PROTEIN BINDING; STEREOISOMERISM; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN;

ANIMALIA;

EID: 33646492299     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.02.001     Document Type: Article

References (59)

1. Pettit G.R., Singh S.B., Hamel E., Lin C.M., Alberts D.S., and Garcia-Kendall D. Experientia 45 (1989) 209
2. Lin C.M., Singh S.B., Chu P.S., Dempcy R.O., Schmidt J.M., Pettit G.R., and Hamel E. Mol. Pharmacol. 34 (1988) 200
3. Pettit G.R., Temple Jr. C., Narayanan V.L., Varma R., Simpson M.J., Boyd M.R., Rener G.A., and Bansal N. Anti-cancer Drug Des. 10 (1995) 299
4. McGown A.T., and Fox B.W. Cancer Chemother. Pharmacol. 26 (1990) 79
5. Dark G.G., Hill S.A., Prise V.E., Tozer G.M., Pettit G.R., and Chaplin D.J. Cancer Res. 57 (1997) 1829
6. Horsman M.R., Ehrnrooth E., Ladekarl M., and Overgaard J. Int. J. Radiation Oncol. Biol. Phys. 42 (1998) 895
7. Tozer G.M., Prise V.E., Wilson J., Locke R.J., Vojnovic B., Stratford M.R.L., Dennis M.F., and Chaplin D.J. Cancer Res. 59 (1999) 1626
8. Galbraith S.M., Chaplin D.J., Lee F., Stratford M.R., Locke R.J., Vojnovic B., and Tozer G.M. Anticancer Res. 21 (2001) 93
9. Kanthou C., and Tozer G.M. Blood 99 (2002) 2060
10. Beauregard D.A., Hill S.A., Chaplin D.J., and Brindle K.M. Cancer Res. 61 (2001) 6811
11. Tozer G.M., Prise V.E., Wilson J., Cemazar M., Shan S., Dewhirst M.W., Barber B.R., Vojnovic B., and Chaplin D.J. Cancer Res. 61 (2001) 6413
12. Chaplin D.J., Pettit G.R., and Hill S.A. Anticancer Res. 19 (1999) 189
13. Grosios K., Holwell S.E., Pettit G.R., and Bibby M.C. Br. J. Cancer 81 (1999) 1318
14. West C.M.L., and Price P. Anti-cancer Drugs 15 (2004) 179
15. Young S.L., and Chaplin D.J. Expert Opin. Investig. Drugs 13 (2004) 1171
16. Hori K., and Saito S. Br. J. Cancer 89 (2003) 1334
17. Guffroy M., Dally C., Vrignaud P., Beys E., and Bissery M.-C. Proc. Am. Assoc. Cancer Res. 45 (2004) abstr. 5438
18. For recent reviews on vascular disrupting agents, see:. Siemann D.W., Chaplin D.J., and Horsman M.R. Cancer 100 (2004) 2491
19. Thorpe P.E. Clin. Cancer Res. 10 (2004) 415
20. Kelland L.R. Curr. Cancer Ther. Rev. 1 (2005) 1
21. Tozer G.M., Kanthou C., and Baguley B.C. Nat. Rev. Cancer 5 (2005) 423
22. For reviews on CA4 analogues, see:. Nam N.-H. Curr. Med. Chem. 10 (2003) 1697
23. Hsieh H.P., Liou J.P., and Mahindroo N. Curr. Pharm. Des. 11 (2005) 1655
24. Woods J.A., Hadfield J.A., Pettit G.R., Fox B.W., and McGown A.T. Br. J. Cancer 71 (1995) 705
25. Sun L., Vasilevich N.I., Fuselier J.A., Hocart S.J., and Coy D.H. Bioorg. Med. Chem. Lett. 14 (2004) 2041
26. Maya A.B.S., Pérez-Melero C., Peláez R., Caballero E., and Medarde M. Bioorg. Med. Chem. 13 (2005) 2097
27. Tron G.C., Pagliai F., DelGrosso E., Genazzani A.A., and Sorba G. J. Med. Chem. 48 (2005) 3260
28. Simoni D., Grisolia G., Giannini G., Roberti M., Rondanin R., Piccagli L., Baruchello R., Rossi M., Romagnoli R., Invidiata F.P., Grimaudo S., Jung M.K., Hamel E., Gebbia N., Crosta L., Abbadessa V., Di Cristina A., Dusonchet L., Meli M., and Tolomeo M. J. Med. Chem. 48 (2005) 723
29. Kaffy J., Monneret C., Mailliet P., Commerçon A., and Pontikis R. Tetrahedron Lett. 45 (2004) 3359
30. Lee G.A. Synthesis (1982) 508
31. Lawrence N.J., Ghani F.A., Hepworth L.A., Hadfield J.A., McGown A.T., and Pritchard R.G. Synthesis (1999) 1656
32. Ramacciotti A., Fiaschi R., and Napolitano E. Tetrahedron: Asymmetry 7 (1996) 1101
33. Weidner-Wells M.A., Fraga-Spano S.A., and Turchi I.J. J. Org. Chem. 63 (1998) 6319
34. 27.
35. Bianchi G., De Micheli C., Gandolfi R., Grünanger P., Vita Finzi P., and Vajna dePava O. J. Chem. Soc., Perkin Trans. 1 (1973) 1148
36. Khadse B.G., Lokhande S.R., Bhamaria R.P., and Prabhu S.R. Indian J. Chem., Sect B 26 (1987) 856
37. Gaukroger K., Hadfield J.A., Hepworth L.A., Lawrence N.J., and McGown A.T. J. Org. Chem. 66 (2001) 8135
38. Kaffy J., Pontikis R., Florent J.C., and Monneret C. Org. Biomol. Chem. 3 (2005) 2657
39. 22.
40. Grünanger P., and Vita-Finzi P. Isoxazoles, Part I. Chemistry of Heterocyclic Compounds Vol . 49 (1991), John Wiley, New York 686-705
41. Gautheron-Chapoulaud V., Pandya S.U., Cividino P., Masson G., Py S., and Vallée Y. Synlett (2001) 1281
42. Joucla M., and Hamelin J. J. Chem. Res. (S) (1978) 276
43. Kanemasa S., Ueno N., and Shirahase M. Tetrahedron Lett. 43 (2002) 657
44. Mukaiyama T., and Hoshino T. J. Am. Chem. Soc. 82 (1960) 5339
45. Kozikowski A.P., and Adamczyk M. J. Org. Chem. 48 (1983) 366
46. Conti D., Rodriquez M., Sega A., and Taddei M. Tetrahedron Lett. 44 (2003) 5327
47. Campbell M.M. In: Barton S.D., and Ollis W.D. (Eds). Comprehensive Organic Chemistry Vol. 4 (1979), Pergamon, Oxford 1004
48. Fürstner A., Weintritt H., and Hupperts A. J. Org. Chem. 60 (1995) 6637
49. Ranu B.C., and Jana U. J. Org. Chem. 63 (1998) 8212
50. Vlahov R., Krikorian D., Spassov G., Chinova M., Vlahov I., Parushev S., Snatzke G., Ernst L., Kieslich K., Abraham W.-R., and Sheldrick W.S. Tetrahedron 45 (1989) 3329
51. Jain N., and Krishnamurty H.G. Indian J. Chem., Sect B 39 (2000) 817
52. Dominguez E., Ibeas E., Martinez de Marigorta E., Palacios J.K., and SanMartin R. J. Org. Chem. 61 (1996) 5435
53. Wu-Wong J.R., Alder J.D., Alder L., Burns D.J., Han E.K.-H., Credo B., Tahir S.K., Dayton B.D., Ewing P.J., and Chiou W.J. Cancer Res. 61 (2001) 1486
54. Li Q., Woods K.W., Clairborne A., Gwaltney S.L., Barr K.J., Liu G., Gherke L., Credo B., Hui Y.H., Lee J., Warner R.B., Kovar P., Nukkala M.A., Zielinski N.A., Tahir S.K., Fitzgerald M., Kim K.H., Marsh K., Frost D., Ng S.-C., Rosenberg S., and Sham H.L. Bioorg. Med. Chem. Lett. 12 (2002) 465
55. Wang L., Woods K.W., Li Q., Barr K.J., McCroskey R.W., Hannick S.M., Gherke L., Credo B., Hui Y.H., Marsh K., Warner R.B., Lee J.Y., Zielinski-Mozng N., Frost D., Rosenberg S.H., and Sham H.L. J. Med. Chem. 45 (2002) 1697
56. Charmantray F., Demeunynck M., Carrez D., Croisy A., Lansiaux A., Bailly C., and Colson P. J. Med. Chem. 46 (2003) 967
57. Mosmann T. J. Immunol. Methods 65 (1983) 55
58. Pettit G.R., Singh S.B., and Cragg G.M. J. Org. Chem. 50 (1985) 3404
59. Combeau C., Provost J., Lancelin F., Tournoux Y., Prod'homme F., Herman F., Lavelle F., Leboul J., and Vuilhorgne M. Mol. Pharmacol. 57 (2000) 553